Showing 4571-4580 of 7006 results for "".
- Emerging Cancer Therapies: Innovations and Challengeshttps://reachmd.com/news/emerging-cancer-therapies-innovations-and-challenges/2471378/In recent years, the field of oncology has witnessed groundbreaking advancements in cancer treatment. From harnessing the body's immune system to precise gene-editing techniques, new therapies are revolutionizing how clinicians approach cancer care.
- Evaluating Methotrexate Safety: Pulmonary Considerations in Autoimmune Diseaseshttps://reachmd.com/news/evaluating-methotrexate-safety-pulmonary-considerations-in-autoimmune-diseases/2471338/In recent years, the interplay between immunosuppressive therapies and pulmonary safety has come under closer scrutiny, especially by specialists in Rheumatology and Pulmonary Medicine. Methotrexate remains a widely used medication due to its effectiveness in manag
- FDA Accepts sNDA for Roflumilast Cream for AD Patients Ages 2-5https://reachmd.com/news/FDA-Accepts-sNDA-Roflumilast-Cream-AD-Patients-Ages-2-5/2471351/The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05%, for the topical treatment of mild to moderate atopic dermatitis (AD) in children 2 to 5 years old, Arcutis Biotherapeutics, Inc. announced. The FDA has se
- Understanding the Heightened Dementia Risk Among Stroke Survivors: A Longitudinal Study Perspectivehttps://reachmd.com/news/understanding-the-heightened-dementia-risk-among-stroke-survivors-a-longitudinal-study-perspective/2471301/A comprehensive Canadian study reveals that stroke survivors are at a remarkably increased risk of developing dementia, particularly within the first year, prompting a reassessment of post‐stroke care strategies and long‐term patient monitoring.
- Revolutionizing Healthcare: The Dual Impact of Telemedicine and Methadone Programshttps://reachmd.com/news/revolutionizing-healthcare-the-dual-impact-of-telemedicine-and-methadone-programs/2471245/In recent years, particularly during the COVID-19 pandemic, telemedicine has emerged as a pivotal tool for maintaining healthcare delivery, while methadone programs have shown promising results in improving HIV care among formerly incarcerated individuals. This article expl
- Dr. Siegel Discusses Sedation Without Drugshttps://reachmd.com/news/Dr-Siegel-Discusses-Sedation-Without-Drugs/2471217/A significant portion of today’s patient population is interested in all-natural alternatives to drugs when possible, and sedation is an area where some useful options exist, according to Daniel M. Siegel, MD. “Sedation without drugs [is important] if you have new-age patients or, I guess,
- Addressing Mental Health Gaps in Inflammatory Arthritis Carehttps://reachmd.com/news/addressing-mental-health-gaps-in-inflammatory-arthritis-care/2471218/Individuals with inflammatory arthritis face an increased risk of depression and anxiety, yet their mental health needs remain inadequately addressed, according to recent studies. Despite frequent healthcare interactions, these patients often receive no more mental health s
- Unraveling the Biomarkers of Prediabetes Trajectorieshttps://reachmd.com/news/unraveling-the-biomarkers-of-prediabetes-trajectories/2471146/Exploring the proteomic and metabolomic signatures can shed light on why some individuals with prediabetes progress to diabetes while others revert to normoglycemia within a year, offering potential biomarkers for predicting these outcomes. Und
- Guselkumab Effective in Psoriasis Regardless of Prior Treatment History: Studyhttps://reachmd.com/news/guselkumab-effective-regardless-of-prior-treatment-history-study/2471126/Guselkumab was effective at managing moderate-to-severe psoriasis over five years, regardless of baseline disease severity or treatment history, according to a post hoc analysis of the VOYAGE 1 and 2 trials. The study looked
- Surgical Excision Outperforms Curettage Plus Imiquimod for nBCChttps://reachmd.com/news/surgical-excision-outperforms-curettage-plus-imiquimod-for-nbcc/2471123/Surgical excision (SE) is significantly more effective than superficial curettage (SC) followed by imiquimod cream, 5%, in maintaining tumor-free survival for nodular basal cell carcinoma (nBCC) after five years, according to a new analysis in JAMA Dermatology.